Nine-source Gene: JY47 Injection New Drug Clinical Trial Application Obtains Clinical Trial Implicit Approval from the National Medical Products Administration.

Nine-source gene announcement, the clinical trial application for the new drug JY47 injection independently developed by the group has been granted the implied approval for clinical trials by the National Medical Products Administration. The indication is metabolic dysfunction-related fat-related hepatitis with liver fibrosis. This product is a monoclonal antibody injection targeting SIRP developed by the group.